3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Cirrhosis
1
Hepato Cellular Carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Gemcitabine
9
Docetaxel
5
Mitomycin
4
erdafitinib
3
durvalumab
3
Cystoscopy
3
disitamab vedotin
2
BCG Vaccine
2
5-aminolevulinic acid hexyl ester
2
tremelimumab
1
tislelizumab
1
monalizumab
1
dodecyl maltoside
1
chondroitin sulfate, sodium hyaluronate drug combination
1
bicalutamide
1
Urine Specimen Collection
1
Transurethral Resection of Bladder
1
Therapeutic Uses
1
Surveys and Questionnaires
1
Saline Solution
1
Patient Discharge
1
Paclitaxel
1
Nonsteroidal Anti-Androgens
1
Monatide (IMS 3015)
1
Mitozytrex
1
Metformin
1
Magnetic Resonance Spectroscopy
1
Laser Therapy
1
Hyaluronic Acid
1
House Calls
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Non-Muscle Invasive Bladder Neoplasms
×
tremelimumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled